Comparison of replicating and nonreplicating vaccines against SARS-CoV-2-Reference-Cited by-同舟云学术

Comparison of replicating and nonreplicating vaccines against SARS-CoV-2

Published:2022-08-26 Issue:34 Volume:8 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Mudrick Haley E.¹^ORCID,Massey Shane²^ORCID,McGlinch Erin B.³⁴^ORCID,Parrett Brian J.³⁴,Hemsath Jack R.³⁵^ORCID,Barry Mary E.⁵,Rubin Jeffrey D.⁴^ORCID,Uzendu Chisom⁴,Hansen Michael J.⁶,Erskine Courtney L.⁶^ORCID,Van Keulen Virginia P.⁶^ORCID,Drelich Aleksandra⁷,Panos Joseph A.⁸^ORCID,Fida Madiha⁵^ORCID,Suh Gina A.⁵^ORCID,Peikert Tobias⁶⁹¹⁰,Block Matthew S.⁶⁹^ORCID,Tseng Chien-Te Kent²⁷¹¹^ORCID,Olivier Gloria R.¹²^ORCID,Barry Michael A.⁵⁶¹³^ORCID

Affiliation:

1. Molecular Pharmacology and Experimental Therapeutics (MPET) Graduate Program, Mayo Clinic, Rochester, MN, USA.

2. Center of Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.

3. Graduate Research Education Program (GREP), Mayo Clinic, Rochester, MN, USA.

4. Virology and Gene Therapy (VGT) Graduate Program, Mayo Clinic, Rochester, MN, USA.

5. Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA.

6. Department of Immunology, Mayo Clinic, Rochester, MN, USA.

7. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.

8. Rehabilitation Medicine Research Center, Musculoskeletal Gene Therapy Research Laboratory, Mayo Clinic Medical Scientist Training Program, Mayo Clinic, Rochester, MN, USA.

9. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

10. Department of Medicine, Division of Pulmonary Care, Mayo Clinic, Rochester, MN, USA.

11. Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, USA.

12. Mayo Clinic Ventures, Mayo Clinic, Rochester, MN, USA.

13. Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Abstract

Most gene-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are nonreplicating vectors. They deliver the gene or messenger RNA to the cell to express the spike protein but do not replicate to amplify antigen production. This study tested the utility of replication in a vaccine by comparing replication-defective adenovirus (RD-Ad) and replicating single-cycle adenovirus (SC-Ad) vaccines that express the SARS-CoV-2 spike protein. SC-Ad produced 100 times more spike protein than RD-Ad and generated significantly higher antibodies against the spike protein than RD-Ad after single immunization of Ad-permissive hamsters. SC-Ad–generated antibodies climbed over 14 weeks after single immunization and persisted for more than 10 months. When the hamsters were challenged 10.5 months after single immunization, a single intranasal or intramuscular immunization with SC-Ad-Spike reduced SARS-CoV-2 viral loads and damage in the lungs and preserved body weight better than vaccination with RD-Ad-Spike. This demonstrates the utility of harnessing replication in vaccines to amplify protection against infectious diseases.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference36 articles.

1. Current State of the First COVID-19 Vaccines

2. IIIa deleted adenovirus as a single-cycle genome replicating vector

3. Amplified and Persistent Immune Responses Generated by Single-Cycle Replicating Adenovirus Vaccines

4. A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus

5. Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview;Heliyon;2024-08

2. A modified recombinant adenovirus vector containing dual rabies virus G expression cassettes confers robust and long-lasting humoral immunity in mice, cats, and dogs;Emerging Microbes & Infections;2024-01-22

3. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms;Cellular & Molecular Immunology;2023-12-26

4. Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine;Current Opinion in Virology;2023-10

5. Protection of SARS-CoV-2 trial vaccines in human is a function of the viral genomes;RPS Pharmacy and Pharmacology Reports;2023-05-01